Tags : Ab

Abbott Receives FDA’s Emergency Use Authorization for its Fourth Ab

Shots: Abbott’s SARS-CoV-2 IgG lab-based serology blood test is the fourth COVID-19 detection test to receive the FDA’ EUA based on Alinity i platforms, which is a next-generation immunoassay instrument offering efficiency to lab clinicians for running tests SARS-CoV-2 IgG lab-based serology blood test is a reliable test for customers and patients to detect Abs […]Read More

Pfizer Extends its Research and License Agreement with BioInvent to

Shots: Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months BioInvent to receive $0.3M as target fees and will get milestones for the development of Ab directed against the target and is eligible to receive further milestones […]Read More

ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop

Shots: ProMab Biotechnologies signs WW license agreement with NantKwest to develop Ab targeting B-Cell Maturation Antigen (BCMA) against myeloma ProMab Biotechnologies get an option to add five chimeric antigen receptor (CAR) targeting sequences based on natural killer (NK) cell therapies NantKwest’s lead NK cell platform includes haNK and taNK designed to induce cell death by […]Read More